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β-Lactamase–producing Escherichia coli, the Most 
Commonly Associated Clinical Manifestation Is Travelers’ 
Diarrhea
Anu Kantele,1,2 Tinja Lääveri,1 Sointu Mero,3 Inka M. K. Häkkinen,1 Juha Kirveskari,3 Brian D. Johnston,4 and James R. Johnson4
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Background. One-third of the 100 million travelers to the tropics annually acquire extended-spectrum β-lactamase (ESBL)–
producing Enterobacteriaceae (ESBL-PE), with undefined clinical consequences.
Methods. Symptoms suggesting Enterobacteriaceae infections were recorded prospectively among 430 Finnish travelers, 90 
(21%) of whom acquired ESBL-PE abroad. ESBL-PE isolates underwent polymerase chain reaction–based detection of diarrhe-
agenic Escherichia coli (DEC) pathotypes (enteroaggregative E. coli [EAEC], enteropathogenic E. coli [EPEC], enterotoxigenic E. coli 
[ETEC], enteroinvasive E. coli, and Shiga toxin–producing E. coli), and extraintestinal pathogenic/uropathogenic E. coli (ExPEC/
UPEC). Laboratory-confirmed ESBL-PE infections were surveyed 5 years before and after travel.
Results. Among the 90 ESBL-PE carriers, manifestations of Enterobacteriaceae infection included travelers’ diarrhea (TD) 
(75/90 subjects) and urinary tract infection (UTI) (3/90). The carriers had 96 ESBL-producing E.  coli isolates, 51% exhibiting a 
molecular pathotype: 13 (14%) were DEC (10 EAEC, 2 EPEC, 1 ETEC) (12 associated with TD) and 39 (41%) ExPEC/UPEC (none 
associated with UTI). Of ESBL-PE, 3 (3%) were ExPEC/UPEC-EAEC hybrids (2 associated with diarrhea, none with UTI). Potential 
ESBL-PE infections were detected in 15 of 90 subjects (17%). The 10-year medical record survey identified 4 laboratory-confirmed 
ESBL-PE infections among the 430 travelers, all in subjects who screened ESBL-PE negative after returning home from their index 
journeys but had traveled abroad before their infection episodes.
Conclusions. Half of all travel-acquired ESBL-producing E. coli strains qualified molecularly as pathogens. Extraintestinal and 
uropathogenic pathotypes outnumbered enteric pathotypes (41% vs 14%), yet the latter correlated more closely with symptomatic 
infection (0% vs 92%). Despite more ESBL-PE strains qualifying as ExPEC/UPEC than DEC, travel-acquired ESBL-PE are more 
often associated with TD than UTI.
Keywords. extended-spectrum beta-lactamase; ESBL; travel; DEC; ExPEC.
International travel drives the global spread of antimicro-
bial-resistant organisms from high- to low-risk regions [1]. 
Visitors to the (sub)tropics have been well documented to ac-
quire multidrug-resistant (MDR) intestinal bacteria: 20%−70% 
carry extended-spectrum β-lactamase (ESBL)–producing 
Enterobacteriaceae (ESBL-PE) at return [2–10].
Colonizing intestinal MDR bacteria may have considerable 
implications for both the community and colonized individuals. 
Such strains can spread silently to close contacts within a com-
munity, in healthcare settings, and eventually even worldwide 
[11]. Colonized travelers usually remain asymptomatic [1], but 
can develop severe, even life-threatening MDR infections [12, 
13]. Infections with MDR strains result in greater morbidity, 
mortality, and economic losses than those caused by suscep-
tible strains [12]. Although one report suggested that imported 
ESBL-PE strains have low pathogenicity [14], no prospective 
study has assessed the clinical infection risk such strains pose.
In studies exploring clinical ESBL-PE isolates, urinary tract 
infection (UTI) has appeared to be the most common type of 
infection caused by travel-acquired MDR bacteria [15]. In a re-
cent study, 9% of travel-acquired ESBL-PE strains carried UTI-
associated virulence factors; data on possible related symptoms 
applyparastyle “fig//caption/p[1]” parastyle “FigCapt”
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of cystitis were not reported [14]. Additionally, retrospective 
studies have identified international travel as a risk factor for 
UTI caused by ESBL-PE [15, 16].
The most common health problem travelers encounter 
is travelers’ diarrhea (TD) [17]. In numerous recent studies 
utilizing multiplex quantitative polymerase chain reaction 
(qPCR) assays, the various diarrheagenic Escherichia coli 
(DEC) pathotypes have been the most frequently detected 
stool pathogens in TD; multiple pathogens often co-occur 
[18, 19]. Although DEC and other enteric pathogens are 
also found among asymptomatic travelers, the prevalence 
is higher among those with TD [18, 19]. Many studies have 
explored acquisition of ESBL-PE during travel [1–10, 20], 
and others have examined TD pathogens [18, 19] and their 
resistance profiles [21, 22]. However, none have investigated 
whether some travel-acquired ESBL-PE isolates actually are 
TD pathogens, as might be expected, given the rising prev-
alence of antibiotic resistance, including ESBL production, 
among TD pathogens [23].
Here, we studied the clinical significance of travel-acquired 
ESBL-PE. Specifically, we prospectively surveyed Finnish inter-
national travelers for symptoms suggesting Enterobacteriaceae 
infections (eg, UTI and TD), screened their feces for travel-ac-
quired ESBL-PE, determined whether the colonizing ESBL-PE 
strains qualified molecularly as DEC or extraintestinal patho-
genic/uropathogenic E.  coli (ExPEC/UPEC), and compared 
clinical data with molecular data. We also reviewed subjects’ 
medical records for clinical ESBL-PE infections during the 
5 years before and after the index travel episode.
MATERIALS AND METHODS
Study Design, Volunteers, Samples, and Travel Destinations
As reported elsewhere, 430 incipient travelers were recruited 
prospectively at the Travel Clinic of Aava Medical Centre [7] 
prior to visiting the tropics. Each subject provided a pre- and 
posttravel stool sample to be screened for ESBL-PE, completed 
a questionnaire before and after their journey, and kept a diary 
while abroad. The Helsinki University Hospital ethics com-
mittee approved the protocol. All subjects provided written in-
formed consent.
Subjects whose posttravel but not pretravel stools yielded 
ESBL-PE were considered to have travel-acquired ESBL-PE. 
Subjects with vs without travel-acquired ESBL-PE constituted 
the ESBL+ and ESBL− groups, respectively. We have previously 
reported risk factors for acquiring ESBL-PE [7]; all subjects but 
1 were the same in both studies.
To identify all possible symptomatic ESBL-PE infections ex-
perienced during travel, we searched for symptoms suggesting 
Enterobacteriaceae infections (described below), then investi-
gated whether subjects with such symptoms had travel-acquired 
ESBL-PE, and whether the strains carried pathotype-defining 
markers for DEC, ExPEC, or UPEC. A  theoretical maximum 
rate of infections caused by travel-acquired ESBL-PE was cal-
culated. Case criteria were as follows: (1) symptoms of an 
Enterobacteriaceae infection; (2) acquisition of ESBL-PE during 
travel; and (3) for TD, the travel-acquired ESBL-PE strain qual-
ified as DEC. For UTI and other Enterobacteriaceae infections, 
no pathotype restrictions applied, since non-ExPEC/UPEC 
also can cause UTI. Despite uncertain causality, this approach 
should identify the maximum rate of infections caused by trav-
el-acquired ESBL-PE (Figure 1).
In addition to exploring ESBL-PE infections during travel, 
we sought for relevant results in the subjects’ medical records. 
To assess whether the index travel increased the risk of clinical 
ESBL-PE infections, the search included 5  years before index 
travel and 5 years after it.
Symptoms of Potential Enterobacteriaceae Infections
As noted above, the posttravel questionnaire and diaries cap-
tured whether while abroad the subject had experienced symp-
toms suggesting Enterobacteriaceae infection (eg, TD or UTI). 
TD was defined as passage of ≥ 3 loose or liquid stools per day, 
or more frequently than normal for the individual [24]. Cystitis 
was defined as dysuria and/or frequency and/or urgency [25], 
and pyelonephritis as a febrile illness (with or without urinary 
symptoms) without diarrhea or respiratory symptoms or other 
obvious cause of fever.
Molecular Identification of Diarrheal and Extraintestinal Pathogens
As detailed previously, fecal ESBL-PE were isolated and char-
acterized using established methods with culture on chromID 
ESBL (bioMérieux, Marcy-l’étoile, France), followed by dou-
ble-disk synergy (Oxoid, Thermo Fisher Scientific, Hampshire, 
United Kingdom) test for cefotaxime (30  µg), ceftazidime 
(30 µg), and cefpodoxime (30 µg), alone or with clavulanic acid 
(10  µg), and species identification by Vitek GN (bioMérieux) 
[7]. Susceptibility testing for ciprofloxacin, cotrimoxazole, ni-
trofurantoin, tobramycin, ertapenem, imipenem, and mero-
penem was performed with Etest (bioMérieux) according 
to criteria set by the European Committee on Antimicrobial 
Susceptibility Testing 5.0 (2018; www.eucast.org). β-Lactamase 
genes (TEM, OXA, SHV, CTX-M) and plasmid-mediated 
AmpC β-lactamase genes (DHA, CIT) were identified with 
multiplex PCR [26].
To identify DEC, isolates underwent multiplex qPCR 
screening for 5 DEC pathotypes—enteroaggregative E.  coli 
(EAEC), enteropathogenic E.  coli (EPEC), enterotoxigenic 
E. coli (ETEC), enteroinvasive E. coli (EIEC), and Shiga toxin–
producing E. coli (STEC)—by a method described previously in 
detail [27]. To identify ExPEC and UPEC, isolates underwent 
multiplex PCR screening for pathotype-defining extraintestinal 
virulence genes [28]. Isolates were designated as ExPEC if pos-
itive for ≥2 of papAH and/or papC (P fimbriae), sfa/foc (S and 
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F1C fimbriae), afa/dra (Dr-binding adhesins), iutA (aerobactin 
system), and kpsM II (group 2 capsule), and as UPEC if posi-
tive for ≥2 of vat (vacuolating toxin), chuA (heme uptake), fyuA 
(yersiniabactin system), and yfcV (adhesin). Isolates could ex-
hibit multiple pathotypes (Table 1).
Major E.  coli phylogenetic group was defined by multiplex 
PCR [29], and sequence type complex (STc; group of closely 
related sequence types [STs]) by a combination of STc-specific 
PCR assays and fumC/fimH typing [30].
Additional Medical Record Screening for Severe Extraintestinal ESBL-PE 
Infections
To identify laboratory-confirmed ESBL-PE infections for 
5 years both before and after travel, we surveyed the subjects’ 
laboratory records for ESBL-PE clinical isolates between 1 
March 2004 and 30 February 2015, and interviewed each pa-
tient with positive findings for additional travel history. The 
Helsinki University Hospital medical records include results 
from the Helsinki University Hospital Laboratory (HUSLAB), 
which serves all public healthcare institutions in the Uusimaa 
region (1.6 million inhabitants). In Finland, nearly all patients 
who are severely ill or need blood cultures are treated in public 
hospitals. Since 2010, patients hospitalized outside the Nordic 
countries within the prior year have been screened for MDR 
organisms upon hospital admission.
Statistical Methods
Statistical analyses were performed with SPSS software version 
22.0 (SPSS Inc, Armonk, New York). The χ2 test or Fisher exact 
test was used to compare categorical variables.
ESBL-E. coli carriers
N = 90
Travellers providing
- stools for ESBL-PE / pathogen analyses
- quesonnaires before and aer travel 
N = 430
ESBL-PE contracted during travel
- 90 travellers
- 96 ESBL-E. coli strains
- 2 ESBL-Klebsiella strains
- 1 ESBL-E.hermannii strains
ESBL noncarriers
N = 340
qPCR analysis for 
DEC virulence markers
10-year medical record review 
for ESBL-PE clinical isolates and 
associated clinical findings
- 5 yrs pretravel
- 5 yrs posravel
ESBL-E. coli strains contracted 
during travel
N = 90
Potenal symptoms of 
Enterobacteriaceae
infecon during travel
collected by quesonnaire
PCR analysis for
ExPEC virulence markers
PCR analysis for
UPEC virulence markers
PCR analysis for
phylogroups and STc
Number of potenal clinical
infecons caused by ESBL-PE either
during or pre / posravel (5 years)
- intesnal
- extraintesnal  (urinary)
Figure 1. Study protocol flowchart. Shown are the 2 groups of volunteers with respect to acquisition of extended-spectrum β-lactamase–producing Enterobacteriaceae 
(ESBL-PE) during travel. For each group, subjects were surveyed regarding symptoms typical of clinical Enterobacteriaceae infections, and travel-acquired ESBL-PE isolates 
were tested for pathotype-defining virulence markers for diarrheagenic Escherichia coli, uropathogenic E. coli, and extraintestinal pathogenic E. coli. Additionally, a medical 
record survey (spanning 10 years: 5 years before and 5 years after travel) was conducted to screen for laboratory-confirmed extraintestinal infections caused by ESBL-PE. 
Abbreviations: DEC, diarrheagenic Escherichia coli; E. coli, Escherichia coli; E. hermannii, Escherichia hermannii; ESBL, extended-spectrum β-lactamase; ESBL-PE, extend-
ed-spectrum β-lactamase–producing Enterobacteriaceae; ExPEC, extraintestinal pathogenic Escherichia coli; PCR, polymerase chain reaction; qPCR, quantitative polymerase 
chain reaction; STc, sequence type complex; UPEC, uropathogenic Escherichia coli.
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RESULTS
Description of Travelers, Travels, and Travel-acquired ESBL-PE
The demographics, destinations, and ESBL-PE colonization 
status of the 430 prospectively recruited international travel-
ers have been reported previously [7]. The 90 (21%) with trav-
el-acquired ESBL-PE constituted the ESBL+ group. Of these, 
61% were females and 66% were aged <50  years; the median 
age was 36.5 years (interquartile range [IQR], 28−58 years), and 
the median journey duration was 16.5 days (IQR, 12−27 days) 
(Table 2). The 90 posttravel stools yielded 99 travel-acquired 
ESBL-PE strains, of which 96 were E. coli, 2 Klebsiella oxytoca, 
and 1 Escherichia hermannii. The 3 non–E.  coli isolates were 
from separate subjects, each also with ESBL-producing E. coli. 
The remaining 340 (79%) subjects constituted the ESBL− group.
Symptoms of Enterobacteriaceae Infection
The only symptoms suggesting Enterobacteriaceae infection re-
ported by ESBL+ group members were those of TD and UTI. Of 
these subjects, 75 of 90 (83%) had TD and 3 of 90 (3%) had UTI 
(specifically, cystitis), the latter including 2 of 49 (4%) females. 
For comparison, in the ESBL− group, 213 of 340 (63%) subjects 
had TD and 13 of 340 (4%) had UTI.
Diarrheal Pathotypes
Of the 96 ESBL-producing E. coli isolates, 13 (14%) qualified as 
DEC, including 10 EAEC, 2 EPEC, and 1 ETEC (no STEC or 
EIEC), each from a different subject (Table 1). Of the 13 sub-
jects with ESBL-producing DEC, 12 (92%) had experienced TD 
while abroad. Eight (62%) had visited South Asia, for which the 
DEC fraction among ESBL-PE isolates was 8 of 29 (28%), vs 5 
of 67 (7%) for all other regions combined (P = .02) (Table 2).
Extraintestinal and Combined Pathotypes
Of the 96 ESBL-producing E. coli fecal isolates, 39 (41%) qual-
ified as ExPEC and/or UPEC, that is, presumptive extraintes-
tinal pathogens (Table 1). Of these, 3 (8%) carried markers of 
combined intestinal and extraintestinal pathotypes (2 EAEC + 
ExPEC, 1 EAEC + ExPEC + UPEC).
Antibiotic Resistance Profiles
Among the 96 isolates, resistance was common to tobramycin, 
ciprofloxacin, and cotrimoxazole, but rare or absent to carbap-
enems and nitrofurantoin (Table 3). Resistance prevalence, 
which varied significantly by pathotype for tobramycin, cipro-
floxacin, and cotrimoxazole, was lowest among DEC isolates, 
intermediate among pathotype-negative isolates, and highest 
among ExPEC/UPEC-only isolates (P < .01 for all comparisons 
of DEC isolates vs ExPEC/UPEC-only isolates).
Phylogroups
Phylogroup distribution and extraintestinal virulence gene 
content varied significantly by pathotype (Table 4). Most 
non-ExPEC/UPEC isolates belonged to phylogroups A and B1, 
whereas nearly all ExPEC/UPEC isolates belonged to groups 
D and F.  Likewise, STc10 predominated among non-ExPEC/
UPEC isolates, whereas STc38, STc405, and STc648 pre-
dominated among ExPEC/UPEC isolates. Consistent with 
the virulence gene–based criteria for ExPEC and UPEC, all 
extraintestinal virulence genes studied were twice or more as 
prevalent among ExPEC/UPEC isolates as among non-ExPEC/
UPEC isolates.
Clinical ESBL-PE Isolates From Medical Record Review
Our 10-year medical record review (5 years before and after 
travel) identified 4 ESBL-PE isolates in clinical samples col-
lected from a presumed focus of infection during routine 
medical care. At the time of the present study, however, the 
corresponding 4 subjects all fell within the ESBL– group. For 
3, the ESBL-PE–positive clinical sample (2, urine; 1, peri-
anal abscess) had been collected before study participation. 
These patients had visited Northern Africa (2 patients) and 
South Asia (1 patient) within 3 months before the ESBL-PE 
infection. The fourth developed ESBL-PE bacteremia and 
peritonitis (related to appendiceal perforation) 4 years after 
study participation, and 2 months after visiting sub-Saharan 
Africa.
Table 1. Pathotypes of 96 Travel-acquired Extended-spectrum β-Lact-
amase–producing Escherichia coli Strains
Category and Pathotype(s) No. (% of 96)
DECa only (ie, not ExPEC/UPEC)
 Any 10 (10)
 EAEC 7 (7)
 EPEC 2 (2)
 ETEC 1 (1)
ExPEC/UPEC only (ie, not DEC)  
 Any 36 (38)
 ExPEC, +/− UPEC 22 (23)
 UPEC, +/− ExPEC 34 (35)
 ExPEC, not UPEC 2 (2)
 UPEC, not ExPEC 14 (14)
 ExPEC + UPEC 20 (21)
DEC + ExPEC/UPEC  
 Any 3 (3)
 EAEC + UPEC 2 (2)
 EAEC + ExPEC + UPEC 1 (1)
Other pathotype combinations  
 DEC or UPEC or ExPEC 49 (51)
 DEC, +/− UPEC/ExPEC 13 (13)
 ExPEC/UPEC, +/− DEC 39 (40)
 ExPEC, +/− DEC 23 (24)
 UPEC, +/− DEC 37 (38)
No pathotype detected 47 (49)
Abbreviations: +/–, with/without; DEC, diarrheagenic Escherichia coli; EAEC, enteroaggre-
gative Escherichia coli; EPEC, enteropathogenic Escherichia coli; ETEC, enterotoxigenic 
Escherichia coli; ExPEC, extraintestinal pathogenic Escherichia coli; UPEC, uropathogenic 
Escherichia coli.
aFive DEC pathotypes (enteroaggregative, enteropathogenic, enterotoxigenic, enteroinva-
sive, and Shiga toxin–producing E. coli).
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Additionally, during the 5-year follow-up, routine stool 
screening cultures upon hospital admission detected ESBL-PE 
colonization in 3 subjects (2 patients, ESBL− group; 1 patient, 
ESBL+ group). All 3 had recently revisited the tropics.
DISCUSSION
Despite growing concern about the surge of antimicrobial resist-
ance among clinical isolates, many clinicians overlook the po-
tential risks asymptomatic intestinal colonization by ESBL-PE 
Table 2. Demographics, Destinations, and Symptoms in Relation to Pathotype Among 90 International Travelers
  Strain Pathotype
Host Characteristic Subjectsa,b ESBL-producing E. coli Strainsc Not DEC or ExPEC/UPECc DEC Onlyc ExPEC/UPEC Onlyc DEC and ExPEC/UPECc
Total 90 (100) 96 (100) 47 (49) 10 (11) 36 (37) 3 (3)
Female gender 49 (54) 54 (56) 24 (51) 5 (50) 24 (67) 1 (33)
Age <50 y 59 (66) 64 (67) 29 (62) 7 (70) 2 (67) 24 (73)
Travel destination       
 South Asia 28 (31) 29 (30) 12 (26) 8 (80) 9 (25) 0 (0)
 Southeast Asia 33 (37) 37 (38) 18 (38) 1 (10) 16 (44) 2 (67)
 Sub-Saharan Africa 23 (26) 24 (25) 14 (29) 0 (0) 10 (28) 0 (0)
 East Asia 2 (2) 2 (2) 0 (0) 1 (10) 1 (3) 0 (0)
 North Africa and Middle East 4 (4) 4 (4) 3 (6) 0 (0) 0 (0) 1 (33)
TD during traveld 75 (83) 81 (84) 36 (77) 10 (100) 33 (92) 2 (67)
UTI during travel 3 (3) 3 (3) 3 (6) 0 (0) 0 (0) 0 (0)
Antibiotic use during travele 28 (31) 32 (34) 15 (33) 2 (20) 15 (42) 0 (0)
Data are presented as no. (%).
Abbreviations: DEC, diarrheagenic Escherichia coli; ESBL-PE, extended-spectrum β-lactamase producing Enterobacteriaceae; ExPEC, extraintestinal pathogenic Escherichia coli; TD, travel-
ers’ diarrhea; UPEC, uropathogenic Escherichia coli; UTI, urinary tract infection.
aThe 90 volunteers acquired a total of 99 ESBL-producing Enterobacteriaceae strains, of which 96 were E. coli, 1 was Escherichia hermannii, and 2 were Klebsiella oxytoca. Each of the 
carriers of the latter 3 strains also had an ESBL-producing E. coli strain. Six volunteers had 2 different ESBL-producing E. coli strains.
bData are given per subject.
cData are shown per strain.
dTypical of TD, many volunteers had concomitant stool pathogens other than the ESBL-DEC shown here.
eInformation missing for 1 traveler who had 2 ESBL-PE strains.
Table 3. Antibiotic Resistance Profile in Relation to Pathotype Among Extended-spectrum β-Lactamase–producing Escherichia coli Strains Acquired 
During International Travela
 Trait Prevalence by Pathotype Category  
Resistance Genotypeb or Phenotypec Total Not DEC or ExPEC/UPEC DEC Only ExPEC/UPEC Only DEC + ExPEC/UPEC 4-Group Comparison P Value
Total 96 (100) 47 (49) 10 (11) 36 (37) 3 (3)
Resistance genes
 TEM 48 (50) 25 (53) 3 (30) 18 (50) 2 (67) .55
 OXA 22 (23) 11 (23) 0 (0) 11 (31) 0 (0) .17
 SHV 4 (4) 2 (4) 1 (10) 1 (3) 0 (0) .78
 CTX-M group 1 67 (70) 30 (64) 8 (80) 28 (78) 1 (33) .23
 CTX-M group 9 26 (27) 13 (28) 1 (10) 10 (28) 2 (67) .28
Resistant or intermediate to antibiotic
 Carbapenem 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) NA
 Tobramycine 49 (51) 23 (49) 2 (20) 24 (67) 0 (0) .042d
 Ciprofloxacin 64 (67) 33 (70) 3 (30) 28 (78) 0 (0) .003d
 Nitrofurantoin 2 (2) 2 (4) 0 (0) 0 (0) 0 (0) .55
 Cotrimoxazole 71 (74) 32 (68) 5 (50) 31 (86) 1 (33) .054d
Data are presented as no. (%) unless otherwise indicated.
Abbreviations: DEC, diarrheagenic Escherichia coli; ExPEC, extraintestinal pathogenic Escherichia coli; NA, not applicable; TD, travelers’ diarrhea; UPEC, uropathogenic Escherichia coli.
aData are given per strain.
bNo strains carried CTX-M group 2, 8, or 25; 1 “DEC only” strain carried DHA; 2 ESBL-PE strains with a negative pathotype analysis; and 1 each “UPEC only” and “ExPEC + UPEC” strains 
carried CIT.
cIsolates testing as resistant or intermediate were recorded as resistant.
dFor DEC-only and DEC + ExPEC/UPEC strains combined vs ExPEC/UPEC-only strains: for tobramycin (2/13 vs 24/36), P = .003; for ciprofloxacin (3/13 vs 28/36), P = .001; and for cotrimox-
azole (6/13 vs 31/36), P = .008 (Fisher exact test, 2-tailed).
eTobramycin data missing for 1 isolate.
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may pose to travelers [31]. Our finding that a large proportion 
of imported ESBL-PE strains qualify molecularly as presump-
tive intestinal or extraintestinal pathogens suggests that more 
travel-acquired ESBL-PE may cause infections than has been 
recognized previously.
We found that 13 of 90 (14%) of the travel-acquired ESBL-PE 
strains were DEC, usually EAEC, a known cause of TD [18, 19, 
32]. Most ESBL-producing EAEC strains originated in South 
Asia, which has the highest rates reported for both TD [17] and 
ESBL-PE acquisition [1], and here had the highest proportion 
of DEC among travel-acquired ESBL-PE strains (28% vs 7% for 
other regions combined).
Recent research on TD has documented stool pathogens 
among both symptomatic and asymptomatic travelers [18, 19], 
rendering causality ambiguous in individual cases. However, at 
the population level, in appropriately controlled studies, EAEC 
[18, 19, 32] and other intestinal pathogens [18, 19] have been 
more prevalent among symptomatic than asymptomatic trav-
elers. Here, 12 of 13 (92%) volunteers with ESBL-producing 
DEC had TD, although (as is typical of TD) 10 of 13 had other 
potentially contributory stool pathogens (Supplementary Table 
1). Thus, although the ESBL-producing DEC strain may not 
have accounted for the symptoms in all 12 TD cases, it probably 
contributed to some, especially the 3 in which ESBL-producing 
EAEC was the sole pathogen detected. Indeed, we have previ-
ously shown within the same cohort, in a 382-subject subgroup 
without antibiotic use, DEC strains to be significantly associ-
ated with TD (for EAEC: odds ratio [OR], 2.6 [95% confidence 
interval {CI}, 1.5–4.4]); for ETEC: OR, 5.9 [95% CI, 2.9−11.9]; 
and for EPEC: OR, 1.7 [95% CI, 1.0−2.7]) [19].
Others have also recently identified ESBL production by 
DEC strains [33]. Given the increasing prevalence of antimicro-
bial resistance among diarrheagenic pathogens [21, 22, 34, 35], 
this phenotype strikes us as especially worrying, since it further 
narrows treatment options if antimicrobial therapy is indicated.
Almost half (41%) of all travel-acquired ESBL-producing 
E. coli exhibited the ExPEC and/or UPEC pathotype, suggest-
ing an increased potential for causing extraintestinal disease. 
However, among ESBL+ group subjects, the only documented 
extraintestinal infections typical of Enterobacteriaceae were 3 
cases of cystitis, all in subjects whose ESBL-producing strain 
was not ExPEC/UPEC. Allowing for the possibility that 
these subjects’ non-ExPEC/UPEC ESBL-PE strains caused 
the cystitis episode, our data suggest a 3% (3/90) maximum 
incidence for extraintestinal infections due to travel-ac-
quired ESBL-producing E. coli. Of note, this low rate appears 
Table 4. Phylogroups, Sequence Type Complexes, and Virulence Genes of 96 Extended-spectrum β-Lactamase–producing Escherichia coli Strains 
Acquired During International Travel
 Trait Prevalence by Pathotype Category  
Trait Category and Specific Trait Total Not DEC or ExPEC/UPEC DEC Only ExPEC/UPEC Only DEC + ExPEC/UPEC P Value
Total 96 (100) 47 (49) 10 (11) 36 (37) 3 (3)
Phylogroupa       
 A 39 (41) 33 (70) 4 (40) 2 (6) 0 (0) < .001
 B1 12 (12) 9 (19) 3 (30) 0 (0) 0 (0) .02
 D 22 (23) 2 (4) 2 (20) 15 (42) 3 (100) < .001
 F 15 (15) 0 (0) 0 (0) 15 (42) 0 (0) < .001
ST complex       
 STc10 28 (29) 24 (51) 2 (20) 2 (6) 0 (0) < .001
 STc38 6 (6) 0 (0) 1 (10) 4 (11) 1 (33) .031
 STc405 7 (7) 0 (0) 0 (0) 7 (19) 0 (0) .005
 STc648 12 (12) 0 (0) 0 (0) 12 (33) 0 (0) < .001
Virulence genes       
 papAH/C 4 (4) 1 (2) 0 (0) 2 (6) 1 (33) .06
 afa/draBC 12 (12) 1 (2) 0 (0) 11 (31) 0 (0) .001
 yfcV 19 (20) 0 (0) 0 (0) 18 (50) 1 (33) < .001
 fyuA 57 (59) 20 (43) 4 (40) 30 (83) 3 (100) .001
 chuA 41 (43) 2 (4) 2 (20) 34 (94) 3 (100) < .001
 iutA 45 (47) 15 (32) 3 (30) 26 (72) 1 (33) .003
 kpsM II 32 (33) 4 (8) 3 (30) 22 (61) 3 (100) < .001
 vat 2 (2) 0 (0) 0 (0) 2 (6) 0 (0) .31
Data are presented as no. (%) unless otherwise indicated.
Abbreviations: afa/dra, Dr-binding adhesins; chuA, heme uptake; DEC, diarrheagenic Escherichia coli; ExPEC, extraintestinal pathogenic Escherichia coli; fyuA, yersiniabactin system; iutA, 
aerobactin siderophore system; kpsM II, group 2 capsule; NA, not applicable; papAH and/or papC, P fimbriae structural subunit and assembly; sfa/foc, S and F1C fimbriae; STc, sequence 
type complex; TD, travelers’ diarrhea; UPEC, uropathogenic Escherichia coli; UTI, urinary tract infection; vat, vacuolating toxin; yfcV, adhesin.
aPhylogroups and ST complexes shown are those represented by ≥5 isolates each. Phylogroups represented by <5 strains each (number of strains): B2 (3), C (4), E (1). ST complexes rep-
resented by <5 isolates each: STc23, STc31, and STc206 (4 isolates each); STc131, STc155, and STc448 (3 isolates each); STc69, STc469, and STc490 (2 isolates each); and STc46, STc70, 
STc86, STc117, STc120, STc205, STc349, STc354, STc446, STc522, STc747, STc875, STc977, STc1140, STc1722, STc3716, and “novel” (1 isolate each).
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applicable only to healthy travelers, since in our recent study 
of ill subjects hospitalized abroad, up to 11% of travelers car-
rying a resistant strain (either ESBL- or carbapenemase-pro-
ducing Enterobacteriaceae) had an extraintestinal infection 
recorded [36].
In previous reports, most carriers of travel-acquired ESBL-PE 
strains have remained asymptomatic [1]; symptomatic/clinical 
ESBL-PE infections have been considered rare [7, 14], with UTI 
as the most common clinical manifestation [15, 37]. Our data 
suggest a theoretical maximum rate of 17% for any sympto-
matic ESBL-PE infection during travel (TD: 12 [13.3%]; UTI: 3 
[3.3%]) among our 90 travelers with travel-acquired ESBL-PE.
We recognize we may have missed some cases in which 
ESBL-producing DEC caused TD but were no longer detected 
upon the subjects’ return to Finland, since travel-acquired 
ESBL-PE sometimes disappear during travel (A. Kantele, un-
published observation). This may be more likely for certain 
DEC types than others; for example, EAEC apparently persists 
longer than ETEC [18]. Likewise, because the posttravel stools 
were collected soon after return, we may have failed to capture 
some nonsevere cystitis and TD episodes, if symptoms devel-
oped only after stool sampling (ie, we may have detected the 
incipient pathogen during its latent/incubation phase, unaware 
that it later caused an infection). With respect to TD, since 12 
of 13 subjects with ESBL-DEC had already reported TD during 
travel, data on (later-occurring) posttravel symptoms could the-
oretically have added at the most only the single subject who 
had not reported TD during travel.
Our theoretical maximum rate of 12 TD and 3 UTI cases 
caused by travel-acquired ESBL-PE among 90 colonized sub-
jects contradicts the common view that UTI is the most fre-
quent clinical consequence of such colonization [15]. Indeed, 
although this is evidently the case in developed countries 
[37], our results—a novel observation—suggest that for trav-
elers visiting tropical regions, TD outnumbers UTI as a clini-
cal correlate of travel-acquired ESBL-PE. This appears logical 
as TD pathogens directly reach their target—ie, the intestinal 
mucosa—while the pathogenesis of UTI requires that the colo-
nizing strains access the urinary tract.
All 3 strains with overlapping intestinal and extraintesti-
nal pathotypes qualified as EAEC, an established association 
[38, 39]. Of note, we have not encountered an overlap be-
tween ExPEC/UPEC and other DEC pathotypes than EAEC. 
Although the selective forces that favor such EAEC-ExPEC/
UPEC hybrid strains remain undefined, EAEC-related adhesins 
may confer both uroepithelial and enterocyte adherence, and 
EAEC can cause UTI [32].
The observed phylogenetic segregation of colonizing DEC 
strains (groups A  and B1; STc10) vs ExPEC/UPEC strains 
(groups D and F; STc38, STc405, STc648) accords with patterns 
identified among clinical isolates [40]. It supports the con-
cept that these divergent pathotypes are mainly derived from 
distinct E.  coli lineages, with the gut microbiota representing 
the (shared) primary reservoir.
Our 10-year medical record survey (spanning 5 pretravel 
and 5 posttravel years) was unlikely to have missed many severe 
posttravel infections treated at other institutions, since these 
medical records cover approximately 90% of all ESBL-PE iso-
lates from clinical samples in the Uusimaa region (Martti Vaara, 
HUSLAB, personal communication). Furthermore, the 5-year 
posttravel survey window should suffice because of the tran-
sience of ESBL-PE colonization (median duration, 3 months), 
with a 1-year posttravel prevalence of only approximately 10% 
[10]. The laboratory records would, however, have missed mild 
diseases such as cystitis, which in most instances is treated em-
pirically per international recommendations, without culture 
[25]. Accordingly, cystitis cases were reliably captured only 
during travel, by our prospective symptom surveillance.
Our medical record survey identified no more than 4 con-
firmed ESBL-PE infections unrelated to the index travel, all 
(paradoxically) among subjects in the ESBL− group. All 4 had 
traveled to a high-risk tropical area within 3 months before their 
clinical ESBL-PE infection, suggesting that they had contracted 
the causative strain during that journey. These data exemplify 
nicely the dynamic and paradoxical nature of the situation. 
Specifically: (1) each journey to an endemic area poses an ap-
preciable risk of contracting ESBL-PE; (2) half of such strains 
are pathogenic E. coli (ExPEC/UPEC > DEC); (3) ESBL-PE col-
onization, although transient, confers a nonzero risk of clinical 
infection (TD more likely than extraintestinal infection); and 
(4) new travel involves new exposure and, thus, renewed risk of 
colonization and, possibly, infection.
CONCLUSIONS
In 13 of 90 (14%) returning Finnish travelers with travel-ac-
quired ESBL-PE, the strains were DEC (mainly EAEC), with a 
high associated TD attack rate (92%). By contrast, in 40% the 
strains represent ExPEC and/or UPEC, yet with no associated 
clinical disease (extraintestinal infection attack rate, 0%). The 
only potential index travel–associated extraintestinal ESBL-PE 
infections were 3 cases of cystitis, involving subjects whose trav-
el-acquired ESBL-producing E. coli strain was neither ExPEC/
UPEC nor DEC. Thus, among travel-acquired ESBL-PE strains, 
the most frequent pathotype is ExPEC/UPEC, yet patho-
type-consistent clinical manifestations are more common 
among hosts colonized by DEC than ExPEC/UPEC strains. The 
maximum total rate of ESBL-PE infections among colonized 
individuals was estimated at 17%; instead of UTI, the most 
commonly associated clinical manifestation of travel-acquired 
ESBL-PE was diarrhea.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases on-
line. Consisting of data provided by the authors to benefit the reader, the 
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